Ambry Genetics patient information may have been used and shared following Tempus AI’s acquisition of Ambry Genetics.
We are investigating potential privacy claims on behalf of individuals who received genetic testing through Ambry Genetics, including CancerNext, CardioNext, EpilepsyNext, ExomeNext, ExomeReveal, +RNAinsight, BRCANext, ColoNext, MelanomaNext, BrainTumorNext, PGLNext, PanxNext, ProstateNext, RenalNext, SNP Array, TAADNext, FHNext, LongQTNext, RhythmNext, HCMNext, and other Ambry genetic testing products and services.
Complete our form for a free, confidential claim review.
What’s Happening
On February 3, 2025, Tempus AI announced it had completed its acquisition of Ambry Genetics. According to allegations in pending litigation, patient information obtained through Ambry genetic testing services may have been used to train artificial intelligence models and may have been shared pursuant to agreements with pharmaceutical companies.
Genetic information is among the most sensitive categories of personal health information. The lawsuit alleges that patients were not provided meaningful notice or an opportunity to opt out before their information was used.
Who Should Contact Us
You may wish to contact us if:
- You received genetic testing services through Ambry Genetics.
- Your testing occurred before February 3, 2025.
- You received testing through products such as CancerNext, CardioNext, EpilepsyNext, ExomeNext, ExomeReveal, +RNAinsight, BRCANext, ColoNext, MelanomaNext, BrainTumorNext, PGLNext, PanxNext, ProstateNext, RenalNext, SNP Array, TAADNext, FHNext, LongQTNext, RhythmNext, HCMNext, or another Ambry testing service.
- You have records, reports, emails, account information, insurance documentation, physician records, or other information showing you received Ambry testing services.
Testing after February 3, 2025, may also be relevant and can be reviewed on a case-by-case basis.
States / Locations Included
We are seeking information from Ambry Genetics patients nationwide, but we are particularly interested in hearing from individuals located in:
- Alaska
- New Hampshire
- New Mexico
- Oregon
FAQ
Why are lawyers investigating this matter?
The investigation concerns allegations that genetic testing information obtained through Ambry Genetics may have been used for AI training purposes and shared under certain business arrangements following Tempus AI’s acquisition of Ambry.
Do I need proof that my information was shared?
No. Attorneys can review your circumstances and determine what information may be helpful.
What if my testing occurred before February 3, 2025?
Individuals tested before February 3, 2025, are of particular interest to the investigation.
What if my testing occurred after February 3, 2025?
You may still wish to contact us. Attorneys can evaluate whether your circumstances are relevant.
Does contacting the firm cost anything?
No. Your case review is free.
Am I joining a lawsuit by filling out the form?
No. Submitting information only allows attorneys to review your situation.
If you received genetic testing through Ambry Genetics, complete our form for a free case review.